Lecanemab granted Fast Track designation by the FDA

Stockholm, December 24, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for ...

BioArctic develops new antibody treatment for ALS

Stockholm, November 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today gave an update on the company’s development project ND3014. For the first time, ...

BioArctic presents Nomination Committee

Stockholm, Sweden, November 1, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 6, 2021, adopted an instruction regarding the appointment ...

Interim Report for the period July – September 2021

Eisai initiates Biologics License Application of lecanemab in the US earlier than expected Events during the third quarter 2021 Eisai has initiated a rolling submission for ...

Interim Report for the period April – June 2021

FDA grants Breakthrough Therapy designation for lecanemab Events during the second quarter 2021 The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for lecanemab ...

Notice of Annual General Meeting in BioArctic AB (publ)

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (the “Company” or “BioArctic”) are hereby summoned to the Annual General Meeting to be held on ...

BioArctic publishes the Annual Report for 2020

Stockholm March 31, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2020 Annual Report has been published. 

Proud partner of: